In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Supernus nets $391.3mm through convertible debt sale

Executive Summary

CNS-focused Supernus Pharmaceuticals Inc. netted $391.3mm through the private placement of $402.5mm in 0.625% senior notes due 2023 (including full exercise of a 30-day option to buy another $52.5mm aggregate principal amount of notes). The notes are convertible at a rate of 16.8545 shares per $1k principal, or $59.33/share. (The stock was averaging $41.56 at the time of the sale.) Supernus will use the proceeds to fund separate but related hedge and warrant transactions and to acquire or partner with other similar companies.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies